Disodium Cromoglycate in Hayfever

Summary Betamethasone valerate aerosol given in doses of 100 μg into each nostril twice daily was compared with a placebo in a double‐blind, cross‐over trial involving thirty patients with seasonal rhinitis. Patients recorded symptoms of eye irritation and watering, sneezing, rhinorrhoea, and nasal blockage, on a diary card. Analysis of the symptom scores showed that nasal symptoms were significantly better on betamethasone valerate than on placebo (P<0.01) and that nasal blockage in particular was improved (P<0.001). The patients’preference was significantly in favour of the active compound (P < 0.02) and no side‐effects were noted. It is concluded that betamethasone valerate offers a safe and effective form of treatment for seasonal rhinitis.

Section: Discussionmentioning

confidence: 99%

Intranasal betamethasone valerate in the treatment of seasonal rhinitis

Archer

Thomas

Harding

1975

“…Sodium cromoglycate inhibits the release of histamine and other mediators of infiammation which occurs when antigen combines with sensitising antibody on mast cells (Foreman & Garland, 1976). In addition to its effectiveness in the treatment of asthma (Altounyan & Howell, 1969;Brompton Hospital/Medical Research Council Collaborative Trial, 1972), rhinitis (Salo, Backman & Holopainen, 1973;Morrison-Smith, 1971), proctitis (Heatley e/a/., 1975) and ulcerative colitis (Manie/a/., 1976), it has also been shown to be effective when applied topically to the conjunctiva in the treatment of vernal conjunctivitis (Rice & Jones, 1973;Tabbara & Arafat, 1977), and in seasonal allergic conjunctivitis (Oosterhuis, 1973;Kazdan et al, 1976).…”

Section: Introductionmentioning

confidence: 99%

Group comparative trial of 2% sodium cromoglycate (Opticrom) with placebo in the treatment of seasonal allergic conjunctivitis

Lindsay-Miller¹

1979

Summary A double‐blind group comparative trial comparing Opticrom with a matching placebo, over a four‐week period, in seasonal allergic conjunctivitis is reported. Overall assessment of treatment benefit made at the end of the trial by the patients and the clinician showed a statistically significant difference in favour of Opticrom. Of the patients on Opticrom, eighteen (90%) said they improved while in the clinicians opinion, seventeen (85%) improved. Six patients using Opticrom and five using placebo complained of stinging of the eyes, while one patient using placebo complained of his eyes becoming bloodshot and watering.

“…Sodium cromoglycate in powder form may itself produce nasal irritation and does not appear to be as effective as had been hoped (Morrison Smith, 1971) although an aqueous solution is more acceptable to the patient and seems more successful (Manners & Ezeoke, 1973). Vasoconstrictor drops are associated with a rebound phenomenon as their effect wears oflT, and antihistamine preparations may slow reaction times or lead to overt drowsiness.…”

Section: Introductionmentioning

confidence: 99%

“…Vasoconstrictor drops are associated with a rebound phenomenon as their effect wears oflT, and antihistamine preparations may slow reaction times or lead to overt drowsiness. Sodium cromoglycate in powder form may itself produce nasal irritation and does not appear to be as effective as had been hoped (Morrison Smith, 1971) although an aqueous solution is more acceptable to the patient and seems more successful (Manners & Ezeoke, 1973).…”

Section: Introductionmentioning

confidence: 99%

Betamethasone valerate in the treatment of summer hay fever

Davidson

Hope

KALlNOWSKI

et al. 1975

Betamethasone valerate nasal aerosol in a daily dose of 400 n% was compared with a placebo in a double-blind trial involving 103 patients with summer hay fever. The patients' and physicians' preference for the active compound was statistically significant (F<0 001), with 88% of the patients receiving betamethasone valerate obtaining substantial relief of symptoms. The analysis of patients' daily symptom scores showed that nasal symptoms were significantly reduced by the active aerosol (/'<0001). A day-by-day comparison of nasal symptom scores with pollen counts indicated a decreasing allergic response as the season progressed; possible reasons for this are discussed. No clinically significant side effects were observed. Short tetracosactrin tests from ten randomly chosen patients on betamethasone valerate showed no abnormality and nasal swabs for Candida culture from a further thirty-two patients were negative. It is concluded that intranasal betamethasone valerate is an effective and safe form of therapy for seasonal rhinitis.